Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Johns Hopkins University

Status: Terminated

Conditions: Retinal Vein Occlusion

Study type: Observational

Funder types: Other

Identifiers

NCT01875770

NA_00079952

Details and patient eligibility

About

This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

Full description

People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

Enrollment: 47 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients who have been enrolled in the following three trials will be included in the study:

A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"

Exclusion criteria

• None

Trial design

47 participants in 1 patient group

Treated with Ranibizumab in previous trial

Description:

Treated with Ranibizumab in previous trial